Perspective Therapeutics, Inc.
Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.
Analyst Andy Hsieh of William Blair initiated coverage on Perspective Therapeutics (CATX) with an Outperform rating, citing its potential in radiopharmaceutical cancer treatments. The firm estimates a fair value of $11.45 per share, significantly higher than its recent closing price of $2.70. Hsieh highlights a $35 billion market opportunity in the U.S. for radiopharmaceuticals, driven by sector growth and Perspective's lead-212-based platform. The stock was trading at $2.86 at the time of publi
Lantheus Alpha Therapy, LLC sold 247,932 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.13 ($3.11–$3.15, $0.78M total) across 2 trades over 2026-09-03 to 2026-09-04. Filed jointly with Lantheus Holdings, Inc. (10% owner).
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CATX (Perspective Therapeutics, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent CATX coverage spans insider activity, financial news and technology.
In the last 30 days, CATX insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($1.6M). The most active reporter was Lantheus Alpha Therapy, LLC with 5 filings.
Price drop indicates negative sentiment, likely from recent data or guidance.
Analyst initiation may lift sentiment and attract new investors, potentially supporting short‑term price appreciation.
Minor insider sell by a large shareholder; unlikely to move price materially.
Minor dilution of insider ownership; unlikely to move price materially.
Small insider sale likely has minimal impact on stock price.
AlphAI scores every news story that mentions CATX with an AI model for sentiment and relevance, and aggregates insider trades from Perspective Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.
2 min readAnalyst Andy Hsieh of William Blair initiated coverage on Perspective Therapeutics (CATX) with an Outperform rating, citing its potential in radiopharmaceutical cancer treatments. The firm estimates a fair value of $11.45 per share, significantly higher than its recent closing price of $2.70. Hsieh highlights a $35 billion market opportunity in the U.S. for radiopharmaceuticals, driven by sector growth and Perspective's lead-212-based platform. The stock was trading at $2.86 at the time of publi
2 min readLantheus Alpha Therapy, LLC sold 247,932 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.13 ($3.11–$3.15, $0.78M total) across 2 trades over 2026-09-03 to 2026-09-04. Filed jointly with Lantheus Holdings, Inc. (10% owner).
1 min readLantheus Alpha Therapy, LLC sold 42,129 shares of Perspective Therapeutics, Inc. (CATX) at $3.11 ($0.13M total) on 2026-09-02. Filed jointly with Lantheus Holdings, Inc. (10% owner).
1 min readLantheus Alpha Therapy, LLC sold 113,914 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.14 ($3.12–$3.14, $0.36M total) across 2 trades over 2026-08-31 to 2026-09-01.
1 min readPerspective Therapeutics (CATX) disclosed that Lantheus Holdings, a 10% owner, sold 35,769 shares at an average price of $3.12, retaining 11.6M shares indirectly. The sale was not part of a 10b5-1 trading plan.
1 min readLantheus Holdings, Inc. sold 35,769 shares of Perspective Therapeutics, Inc. (CATX) at $3.12 ($0.11M total) on 2026-09-01.
1 min readLantheus Holdings, Inc. sold 78,145 shares of Perspective Therapeutics, Inc. (CATX) at $3.14 ($0.25M total) on 2026-08-31.
1 min readPerspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results • Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 s
6 min readPerspective Therapeutics (NYSE American: CATX) appointed Paul Lyne, Ph.D. as Chief Science Officer, joining from Merck KGaA. Co-founder Michael K. Schultz, Ph.D. moved to Senior Scientific Advisor. The release cites Lyne’s 25+ years in oncology and work on 30+ oncology programs, and notes Perspective’s clinical-stage radiopharmaceutical pipeline.
2 min read
